25-27 February, 2019
London, UK
250+Attendees ♦ 40 World Class Speakers   33+ Case Studies ♦ 2 Tracks  6 Deep Dive Discussion Sessions 



Dale Ludwig
Chief Scientific Officer
Actinium Pharmaceuticals

Dale L. Ludwig, Ph.D. is the Chief Scientific Officer at Actinium Pharmaceuticals. He directs discovery and translational Research for the Company’s novel antibody radioimmunoconjugate (ARC) pipeline and he plays an integral role in advancing Actinium’s novel Iomab-ACT program for targeted lymphodepletion in preparation for adoptive cell therapy. Dale is also responsible for the advancement of the Company’s Actinium Warhead Enabling (AWE) platform, partnerships and its supporting technology and intellectual property. He has 21 years industry experience in oncology antibody drug discovery and development, including 9 years at Eli Lilly and Company heading Oncology Biologics Technology where Dale and his team advanced multiple biologics into clinical testing and supported the successful development and launch of several therapies including Erbitux and Cyramza.

Barbra Sasu
Chief Scientific Officer
Allogene Therapeutics

Barbra Sasu is currently the CSO of Allogene, a newly-formed allogeneic CAR T company which is an amalgam of the successful Kite management team who delivered regulatory approval of Yescarta,with the technical team who developed the Pfizer CAR T pipeline.Barbra received her PhD from the Paterson Institute for Cancer Research in Manchester, UK in the laboratory of T. Michael Dexter, FRS and conducted her postdoctoral research at Harvard in the laboratory of T Keith Blackwell.  She joined Amgen in 2001 working on normal and malignant hematology initially, transferring to broader cancer biology and finally to immuno-oncology (IO) with a large emphasis on T cell redirective therapies;specifically BiTE molecules.  In 2013 she joined Pfizer to become involved with large molecule IO including the Pfizer T cell redirection programs and led diligence to look for a CAR T collaboration partner.

Day One

Tuesday 26th February, 2019

09.15 | Industry Leaders' Fireside Chat

Christian Itin
Chief Executive Officer

Christian Itin joined Autolus as Chairman of the Board of Directors at the inception of the company and subsequently also took on the role of Chief Executive Officer. Previously he was Chief Executive Officer and Chairman of the Board of Directors of Cytos Biotechnology Ltd, a public biotechnology company that merged with Kuros Biosurgery Holding Ltd, and he now serves as Chairman of the Board of Directors of the merged entity, renamed Kuros Biosciences Ltd. He also serves as a Non-Executive Director of the UK-based human antibody company, Kymab Ltd. Prior to joining Cytos, Christian was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company which was acquired in March 2012 by Amgen, Inc. for USD 1.2 billion in cash. Micromet pioneered T-cell engaging antibodies and with blinatumomab developed the first approved product in this field. After serving in senior management roles at Micromet, Christian was appointed Chief Executive Officer in 2004. Prior to joining Micromet in 1999, Christian co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA. He received a diploma in biology and a PhD in cell biology from the University of Basel, Switzerland. In addition, he also performed post-doctoral research at the Biocenter of Basel University and at Stanford University School of Medicine, CA, USA.

Day One

Tuesday 26th February, 2019

09.15 | Industry Leaders' Fireside Chat

Vicki Coutinho
Senior Director, Regulatory Affairs

Vicki has been instrumental in bringing multiple Chimeric Antigen Receptor (CAR) T cell programs into the clinic at Autolus Limited, a biotech company that specialises in advanced T cell programming. Vicki joined Autolus after a decade in the CRO industry where she was responsible for the regulatory strategy of 200+ products and various lifecycle regulatory applications. She also developed the department that managed 12,000+ global clinical trial applications and INDs.  Previously, Vicki worked for Fibrocell Science and was integral to the process optimisation, manufacture and regulatory interactions for one of the first autologous cell therapies approved by the FDA.

Jie Jia
Vice President, Strategic Alliances
CARsgen Therapeutics

Before joining CARsgen, Dr. Jia had been working in Cleveland Clinic for 12 years with increasing responsibility as Research Associate Staff, Core Facility Manager, Project Scientist in Molecular, Cellular Medicine, and Manager of Macromolecular Interaction Core. Dr. Jia had more than 25 immunology research publications in prestigious scientific journals including Cell and Nature. Dr. Jia also holds decent experience in GLP/GMP/GCP compliance and core facility management, CMO/CRO evaluation and management, market analysis, and technology evaluation. In addition, Dr. Jia was Editorial Board Members for a couple of research journals. Dr. Jia acquired his Ph.D. degree in Biochemistry and Molecular Biology from Institute of Biochemistry and Cell Biology, Chinese Academy of Science in 2004.

Zonghai Li
Chief Executive Officer
CARsgen Therapeutics

Dr. Li is a professor in Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine. Dr. Li got his M.D. and Ph.D. from Hunan Medical University and Fudan University respectively. Dr. Li is dedicated to developing innovative immune therapeutics to fight cancer. He has advanced several first-in-class CAR-T cell therapeutics for the treatment of patients with pancreatic, gastric, liver cancer and other cancer types.

Tony Ho
Executive Vice President, Head of Research & Development
CRISPR Therapeutics

Dr. Tony Ho is Executive Vice President, Head of Research and Development at CRISPR Therapeutics over seeing development of allogenic CAR-T, hemoglobinopathy and regeneration medicine.  He was previously Senior Vice President and Head of Oncology Integration and Innovation at AstraZeneca. During his tenure at AstraZeneca, he oversaw both development and commercialization of the two key drugs – Lynparza, a first-in-class PARP inhibitor and Imfinizi (anti-PD-L1), AstraZeneca’s first immuno-oncology drug. Prior to joining AstraZeneca, Tony was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., Inc. and led multiple development programs including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Prior to joining Merck, Tony was the Co-Founder and Chief Scientific Officer of Neuronyx, Inc., a regenerative medicine company. Tony completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine. After an internship in Internal Medicine at the Massachusetts General Hospital, Tony completed his residency and neurophysiology fellowship in the Department of Neurology at the Johns Hopkins Hospital. He was Assistant Professor at Johns Hopkins Hospital in the areas of neuropathy and neuromuscular diseases. Tony describing and elucidating the pathogenesis of a new disease called "acute motor axonal neuropathy (AMAN)". He has published widely in several fields with over 80 papers and is co-inventor of 14 patents. He is currently adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor (Part-time) of Neurology at Johns Hopkins University.

Stefanos Theoharis
Senior Vice President, Corporate Development & Partnering
Cell Medica

Stefanos joined Cell Medica to lead our partnering activities, bringing a combination of academic, business development, project management and finance skills. Following his PhD, Stefanos worked as a post-doctoral researcher at Imperial College, whilst also worksing for six years in parellel as a paid consultant to the London Technology Network, a government-funded organization bridging the gap between industry and academia. Subsequently, Stefanos joined Lazard, the investment bank, as a member of the Life science M&A team and then Roche Partnering, as Director of Emerging Technologies, where he participated in multiple licensing deals, with a focus on novel innovative technologies. He then joined Antisense Pharma as Head of BD. Prior to joining Cell Medica, Stefanos was CBO for apceth in Munich, where he was responsible for business development on the company’s first-in-man engineered cell therapy platform and its GMP manufacturing business, as well as project management, and communications.

Stephane Depil
Senior Vice President Research & Development & Chief Medical Officer

Prof. Stéphane Depil, M.D., Ph.D., is Executive Vice President of Research & Development and Chief Medical Officer at Cellectis. In addition to this role, Stéphane Depil is an onco-hematologist at Léon Bérard Cancer Center and an adjunct Professor at University Claude Bernard Lyon 1, France. Prof. Depil is a Board-certified physician in hematology and has a PhD in Immunology. He has over 15 years of experience in oncology preclinical and clinical development, both in academic centers and pharmaceutical companies. He previously served as Chief Executive Officer at Netris Pharma and Head of Oncology Research and Development at Servier Research Institute.

David Gilham
Vice President, Research & Development

Dr. David Gilham first joined Celyad in April 2016 as member of the Scientific Advisory Board. As from September 1st, 2016, David became Vice-President R&D, heading the implementation of our Research and Development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.

Detlev Parow
Head of Department of Medicines, Therapeutic Appliances & Remedies Product & Billing Management Division

Since 2010 Dr. Detlev Parow is Head of the Department Care Management Development at DAK-Gesundheit in Hamburg. From 2002 to 2009, he worked for Hamburg Münchener, initially leading the Medical Competence Center, later the Department of Care Management. From 1999 to 2002, he was responsible for the medical advisory service of ProCOMED/4sigma GmbH in Hamburg and Oberhaching near Munich. After completing his medical studies in Hamburg in 1981, he worked until 1999 as an anesthesiologist in various hospitals in Hamburg. From 1982 to 1983 he worked in Liberia and Burkina Faso as a scientific researcher for the Institute for Tropical Diseases, Hamburg. Dr. Parow is a freelance lecturer at the University of Hamburg.

Bob Valamehr
Chief Development Officer & Vice President Cancer Immunotherapy
Fate Therapeutics

Bahram (Bob) Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

Cedrik Britten
Head of Oncology Cell Therapy Research Unit

Cedrik is a physician and immunologist working in the field of Immuno-Oncology since 1998. From 2001 to 2008 he worked in haematology and blood transfusion departments and conducted translational research on tumour-specific T cells and anti-cancer vaccines trials. Cedrik joined BioNTech AG in 2008 where he drove the company’s growth to a mid-sized enterprise of 250 FTE. As Vice President R&D his translational team was the first to test highly personalized mutanome vaccines in melanoma patients. Cedrik joined GSK in 2015 and is heading the Oncology Cell Therapy Research Unit (OCT RU). The current R&D activities cover the non-clinical and clinical development of TCR-T & CAR-T cells, technologies to enhance patient benefit of engineered lymphocytes in solid cancer, innovative ways to supply autologous cell products, and the discovery of new targets for CAR-T cell approaches.

Harpreet Singh
Chief Executive Officer
Immatics US

Harpreet Singh co-founded Immatics in 2000. Since then he has served as Managing Director and Chief Scientific Officer of Immatics Biotechnologies GmbH, helping to grow the company from a start-up to an established biotech and playing a leading role in raising over US$350m of funding through private equity, grants and licensing agreements. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapies with clinical utility. Since 2015, Harpreet Singh is President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston, Texas as to develop next-generation Adoptive Cell Therapies (ACT).

Will Singleterry
Associate Director, Business Development

Will Singleterry received his Doctoral Degree from the University of Mississippi Medical Center and completed his Post-Doctoral Training at St. Jude Children’s Research Hospital.  He now serves as the Associate Director of Business Development for IsoPlexis, a venture capital-funded life sciences company dedicated to accelerating the fight against cancer through its single-cell proteomics platform.  Will manages collaborations with Bio-Pharmaceutical partners, using IsoPlexis’ single-cell technologies to reveal the highly functional cell subsets driving clinical response in Immunotherapy.

Marc Kamp
Director CAR-T Product Distribution & Supplier Quality Management
Kite Pharma

I support the Gilead country affiliates in Europe/ROW for the management and distribution of KitePharma (CAR T) products in their country. In addition I am now building Supplier Quality Management in Europe for Kite Pharma. This includes Quality Oversight of contract manufacturing organizations (CMO), contract test labs(CTL) and GMP service providers (calibration, cleaning, software suppliers, specialty couriers, andthird party logistics) as well as raw material suppliers for CAR T manufacturing in Europe.

John Maher
Chief Scientific Officer
Leucid Bio

Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and the Royal Free NHS Foundation Trust, at Barnet Hospital.

Juan Vera
Chief Development Officer
Marker Therapeutics

For the past 12 years, Juan F. Vera has worked extensively on developing novel T cell therapies and optimizing manufacturing processes for clinical applications at the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine. In collaboration with Wilson Wolf Manufacturing, he has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. Dr. Vera has extensive expertise in developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability. Dr. Vera has previously collaborated with Celgene and Bluebird Bio in developing novel CAR T cell therapies. He has also been the recipient of different prestigious awards including the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera attained his M.D. from the University El Bosque in Bogota, Colombia.

Peter L. Hoang
President & Chief Executive Officer
Marker Therapeutics

Peter L. Hoang brings over twenty years of immuno-oncology, investment banking, venture capital, and public company executive management experience to Marker Therapeutics, Inc., serving most recently as President & CEO of TapImmune Inc. (Nasdaq: TPIV), one of the predecessor companies that merged to form Marker Therapeutics. He has also served as Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM). Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. There, he led the commercialization of MD Anderson’s Sleeping Beauty transposon-based CAR-T program, resulting in the largest public company-to-academic research institution upfront deal in history. Before joining MD Anderson, Mr. Hoang was a Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He also served as a senior investment banker in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.

Dolores Schendel
Chief Executive Officer & Chief Scientific Officer

Prof. Dolores J. Schendel holds the positions of CEO/CSO of Medigene AG, a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried, Germany. In addition, she is Managing Director of Medigene Immunotherapies GmbH, a subsidiary of Medigene that she and coworkers founded as a spin-off of the Helmholtz Center Munich in 2013, and was acquired by Medigene in January 2014. Prof. Schendel served from 1998-2014 as Director of the Institute of Molecular Immunology of the Helmholtz-Center Munich - German Research Center for Environmental Health. She also holds a professorship in immunology at the Ludwig Maximilian University of Munich since 1986.

Kai Pinkernell
Chief Medical Officer & Chief Development Officer

Dr. Kai Pinkernell is the Chief Medical Officer/Chief Development Officer at Medigene AG and responsible for the areas of Clinical Affairs, RA/QA and CMC. Medigene AG is a stock listed (Frankfurt: MDG1, Prime Standard) biotechnology company with its headquarters in Martinsried, Munich. Medigene concentrates on the development of personalized T cell-based immunotherapies with projects in pre-clinical and clinical development.

James McBlane
Preclinical Assessor, MHRA & Member, Committee for Advanced Therapies (CAT)

Dr McBlane’s completed BSc and PhD degrees in pharmacology and worked for the  pharmaceutical firm, Wellcome, moving to the Medicines Control Agency and then to the Japanese biopharmaceutical company, Chugai.  He returned to the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) in 2005.  He has worked on thousands of clinical trials and hundreds of marketing authorisation applications and given development advice to score of companies.  From 2013, he was alternate UK delegate to the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT); from January 2018, he was alternate delegate from CAT to EMA’s Scientific Advice Working Party (SAWP).

Katharina Winnemöller
Marketing Manager for Clinical Cell Processing and T Cell Applications
Miltenyi Biotec

Katharina studied Biology at the University of Vienna and received her PhD at the Institute of Molecular Pathology. She has been with Miltenyi Biotec since 2007 in various roles (Clinical Development, Marketing, Sales) and is now the Global Marketing Manager Clinical Cell Processing.

Pilar Pinilla
Dominguez Senior Scientific Adviser

Pilar Pinilla-Dominguez, Senior Scientific Adviser, NICE Scientific Advice Pilar is involved in NICE scientific advice projects and parallel scientific advice with other HTAs and regulatory agencies. Pilar leads the technical development of International services at NICE and participates in educational seminars and business development activities for scientific advice, with a particular focus on cell and gene therapies and highly specialised technologies. Pilar holds a University degree in Business Administration and Management from University of La Laguna (Spain). She also has an MSc in Health Economics, Policy and Law with specialisation in Health Economics from the Erasmus University of Rotterdam (The Netherlands). Pilar joined NICE in 2012 as part of the Technology Appraisals and the Highly Specialised Technologies programme. Before joining NICE, Pilar worked as a Researcher in one of the Spanish regional HTA units conducting systematics reviews and economic evaluations for the Spanish Healthcare System.

Therese Choquette
Analytical Project Leader, Cell & Gene Therapy Development and Manufacturing

Therese Choquette is an Analytical Project Leader in Novartis Cell and Gene Therapy Development and Manufacturing working with CART cells. She received her M.S. in Medical Science in Biomedicine and Ph.D. in Rheumatology from the Karolinska Institute in Stockholm, Sweden. With an interest in immunology and immune responses she did her postdoc in the lab of Dr. Kornfeld at University of Massachusetts Medical School in Worcester, MA investigating effects of hyperglycemia on host defense in tuberculosis. Prior to joining Novartis in 2014 she was leading a R&D Applied Research team at Organogenesis Inc. in Canton, MA.

Francesco Marincola
Chief Scientific Officer
Refuge Biotech

Dr. Marincola is Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California. He was previously Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications and Clinical and Translational Medicine. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning author of The Wise Men of Pizzo and Cat Behind the Window.

Jim Freeth
Co-managing Director

Dr Jim Freeth co-founded Retrogenix following 10+ years in management within the biotechnology and pharmaceutical industry. Within Retrogenix, Jim plays a key role in establishing and managing interactions with commercial and academic clients, and oversees the company’s marketing activities. Jim is a biologist by training, obtaining his PhD at the University of Manchester, UK, in 1997. Following two years at the gene therapy company Oxford Biomedica (Oxford UK), Jim moved to AstraZeneca pharmaceuticals in 2000. At AstraZeneca, Jim led multi-disciplinary technology development projects and managed several external biotechnology collaborations, delivering valuable technologies into the business. Subsequently, Jim worked in the Osteoarthritis and Analgesia therapeutic areas, where he introduced and progressed numerous projects within AstraZeneca’s Discovery portfolio.

Véronique Blanc
Immuno-Oncology Program Director

Véronique Blanc, Ph.D, joined Servier end 2016 as Head of Immuno-Oncology Program. She received her PhD in Microbiology and Molecular Biology at Pasteur Institute, Paris, in 1989, and graduated later in Immunology at University René Descartes, Paris. She has been working for more than 25 years in Drug Discovery in Pharma from target to IND. She was previously leading the Oncology Biologics Discovery team in Sanofi and brought a  number of Biologics programs to clinic, now in Phase I to III, in solid tumors and hematological malignancies. Her major interest today is Immuno-Oncology, with the ambition to bring innovation at the heart of the projects, in close partnership with Academic labs and Biotechs.

Michael Leek
Chief Executive Officer
TC Biopharm

Chief Executive at TC BioPharm, Michael has 28 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.  

Alfonso Quintás Cardama
Chief Medical Officer
TCR2 Therapeutics

Dr. Quintás joined TCR2 in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás was the clinical development head of the Cell & Gene Therapies Unit at GlaxoSmithKline where he was responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on affinity enhanced T-cell therapies. Previously, he served as Global Clinical Leader of Novartis’ now approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Quintás earned his MD from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine, Albert Einstein College of Medicine in New York and a Hematology and Oncology fellowship at The University of Texas, MD Anderson Cancer Center.

Dan Ollendorf
Director Value Measurement & Global Health Initiatives
Tufts University Center for the Evaluation of Value and Risk in Health, CEVR

Dan Ollendorf is Director of Value Measurement and Global Health Initiatives at the Tufts University Center for the Evaluation of Value and Risk in Health (CEVR).  An internationally recognized expert in health technology assessment (HTA), Dan’s research interests including expanding the use of HTA and economic evaluation in developing and rapidly-growing economies, as well as refinement and use of value assessment tools in the US and other developed settings.  Prior to joining CEVR, Dan was Chief Scientific Officer for the Institute for Clinical and Economic Review (ICER) for over 10 years, where he oversaw the broader HTA process and managed relationships with multiple stakeholders and research collaborators.

Qasim Rafiq
Senior Lecturer in Bioprocessing of Regenerative, Cellular and Gene Therapy

Dr Qasim Rafiq is an Associate Professor at University College London in Cell and Gene Therapy Bioprocessing. He is a multidisciplinary engineer and currently leads a research portfolio of >£3M focusing on the bioprocessing, automation and biomanufacture of ATMPs. . He has specific interest in addressing the large-scale manufacturing challenges and enhancing process and product understanding to enable successful translation from the laboratory to the clinic. He is both a Chartered Engineer (CEng) and Chartered Scientist (CSci) and sits on multiple scientific and engineering committees including the BIA’s Cell and Gene Therapy Advisory Committee and the BSI’s Biotechnology Standards Group.

Miguel Forte
Chief Executive Officer
Zelluna Immunotherapy

Currently the CEO of Zelluna Immunotherapy and visiting Professor at the Lisbon and Aveiro Universities in Portugal. Currently also serving as Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy (ISCT). From February 2006 to January 2010 was VP of Global Medical Affairs at UCB. In 2004, joined Nabi Pharmaceuticals as the VP of Clinical, Medical and Regulatory Affairs in Europe. After several clinical, academic and regulatory positions in the public sector in Portugal and at the EMA, spent six years with Bristol-Myers Squibb in various positions including Country Medical Director, Executive Director of Infectious Diseases, Immunology and Dermatology and VP of International Medical Organization in Portugal and Belgium. Holds an M.D. from the Faculty of Medicine of the University of Lisbon, Portugal, and a Ph.D. in Immunology from the University of Birmingham, UK, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies (HEP). He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.

Day One

Tuesday 26th February, 2019

09.15 | Industry Leaders' Fireside Chat

Laurence Cooper
Chief Executive Officer
Ziopharm Oncology

Laurence joined Ziopharm Oncology as chief executive officer in 2015 after Ziopharm and Intrexon Corporation together licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

Jens Hasskarl
Senior Director, Research Development, Clinical & Medical
Celgene Corporation

Board-certified hematologist and medical oncologist with very strong scientific and clinical background and pharmaceutical experience in cell and gene therapy (chimeric antigen receptor therapy) Global Clinical Development Cell and Gene Therapy. Phase I through IV, clinical development, general management, team leadership and development, and business development

Maureen Graham
Managing Director
Diamond Pharma Services

Andreas Göbel
Executive and Technology Lead
Hypertrust Patient Data Care

Andreas Göbel is executive lead and the technology mastermind of Hypertrust Patient Data Care and its first innovation Hypertrust X-Chain. After spending more than 15 years in research and development at SAP SE in Walldorf and several years in blockchain technologies and cryptocurrencies, he combines these competences in his role at Hypertrust Patient Data Care to innovate groundbreaking patient-centered business applications for pharma and healthcare. Andreas firmly believes that technological megatrends like blockchain, artificial intelligence and the internet of things have the power to make a positive difference to people’s lives and patients’ treatments.

Kai Wilkens
Senior Director Europe ACD